Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy

Thomas F. Chromecki, Eugene K. Cha, Karl Pummer, Douglas S. Scherr, Ashutosh K. Tewari, Maxine Sun, Harun Fajkovic, Claus Roehrborn, Raheela Ashfaq, Pierre I. Karakiewicz, Shahrokh F. Shariat

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

OBJECTIVE: • To evaluate the association of insulinlike growth factor II mRNA binding protein 3 (IMP3) with pathological features and outcomes in patients treated with radical prostatectomy (RP). PATIENTS AND METHODS: • Immunohistochemical staining for IMP3 was performed on archival tissue microarray specimens from 232 consecutive patients treated with RP for clinically localized disease. • None of the patients received neoadjuvant or adjuvant radiation or hormone therapy. • IMP3 expression was histologically categorized as normal or abnormal. • Disease recurrence was classified as aggressive if metastases were present, post-recurrence prostate-specific antigen (PSA) doubling time was less than 10 months, or if the patients failed to respond to salvage local radiation therapy. RESULTS: • The median follow-up was 69.8 months (interquartile range [IQR]: 40.1-99.5). • IMP3 expression was abnormal in 42 (18.1%) of 232 patients. • IMP3 expression was associated with extracapsular extension (P = 0.020), seminal vesicle invasion (P = 0.024), lymphovascular invasion (P = 0.036) and a high pathological Gleason score (P = 0.009). • The 5-year PSA recurrence-free survival for IMP3-negative patients was 83% (standard error [SE] = 3) vs 67% (SE = 8) in IMP3-positive patients (log-rank test, P = 0.015). • In a multivariable analysis that adjusted for the effects of surgical margins, extracapsular extension and seminal vesicle invasion, PSA (hazard ratio [HR]: 1.04, P = 0.013), lymph node metastasis (HR: 16.7, P < 0.001) and a high pathological Gleason score (HR 4.3, P = 0.008) were significantly associated with PSA recurrence-free survival, whereas IMP3 expression was not (P = 0.11). Similarly, IMP3 expression was only associated with aggressive recurrence (HR 3.2, P = 0.006). CONCLUSION: • IMP3 expression is abnormal in approximately one-fifth of prostate cancers. Although IMP3 is differentially expressed in patients with features of biologically aggressive prostate cancer, it does not have an independent prognostic value in patients treated with RP.

Original languageEnglish (US)
Pages (from-to)63-68
Number of pages6
JournalBJU International
Volume110
Issue number1
DOIs
StatePublished - Jul 2012

Fingerprint

Insulin-Like Growth Factor II
Prostatectomy
Carrier Proteins
Messenger RNA
Prostate-Specific Antigen
Recurrence
Neoplasm Grading
Seminal Vesicles
Prostatic Neoplasms
Neoplasm Metastasis
Survival
Intercellular Signaling Peptides and Proteins
Radiotherapy
Lymph Nodes
Hormones
Radiation
Staining and Labeling

Keywords

  • Biomarker
  • IMP3
  • Prognosis
  • Prostate cancer
  • Recurrence

ASJC Scopus subject areas

  • Urology

Cite this

Chromecki, T. F., Cha, E. K., Pummer, K., Scherr, D. S., Tewari, A. K., Sun, M., ... Shariat, S. F. (2012). Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy. BJU International, 110(1), 63-68. https://doi.org/10.1111/j.1464-410X.2011.10703.x

Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy. / Chromecki, Thomas F.; Cha, Eugene K.; Pummer, Karl; Scherr, Douglas S.; Tewari, Ashutosh K.; Sun, Maxine; Fajkovic, Harun; Roehrborn, Claus; Ashfaq, Raheela; Karakiewicz, Pierre I.; Shariat, Shahrokh F.

In: BJU International, Vol. 110, No. 1, 07.2012, p. 63-68.

Research output: Contribution to journalArticle

Chromecki, TF, Cha, EK, Pummer, K, Scherr, DS, Tewari, AK, Sun, M, Fajkovic, H, Roehrborn, C, Ashfaq, R, Karakiewicz, PI & Shariat, SF 2012, 'Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy', BJU International, vol. 110, no. 1, pp. 63-68. https://doi.org/10.1111/j.1464-410X.2011.10703.x
Chromecki, Thomas F. ; Cha, Eugene K. ; Pummer, Karl ; Scherr, Douglas S. ; Tewari, Ashutosh K. ; Sun, Maxine ; Fajkovic, Harun ; Roehrborn, Claus ; Ashfaq, Raheela ; Karakiewicz, Pierre I. ; Shariat, Shahrokh F. / Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy. In: BJU International. 2012 ; Vol. 110, No. 1. pp. 63-68.
@article{501940988fc540b8a429c1ec7ae06132,
title = "Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy",
abstract = "OBJECTIVE: • To evaluate the association of insulinlike growth factor II mRNA binding protein 3 (IMP3) with pathological features and outcomes in patients treated with radical prostatectomy (RP). PATIENTS AND METHODS: • Immunohistochemical staining for IMP3 was performed on archival tissue microarray specimens from 232 consecutive patients treated with RP for clinically localized disease. • None of the patients received neoadjuvant or adjuvant radiation or hormone therapy. • IMP3 expression was histologically categorized as normal or abnormal. • Disease recurrence was classified as aggressive if metastases were present, post-recurrence prostate-specific antigen (PSA) doubling time was less than 10 months, or if the patients failed to respond to salvage local radiation therapy. RESULTS: • The median follow-up was 69.8 months (interquartile range [IQR]: 40.1-99.5). • IMP3 expression was abnormal in 42 (18.1{\%}) of 232 patients. • IMP3 expression was associated with extracapsular extension (P = 0.020), seminal vesicle invasion (P = 0.024), lymphovascular invasion (P = 0.036) and a high pathological Gleason score (P = 0.009). • The 5-year PSA recurrence-free survival for IMP3-negative patients was 83{\%} (standard error [SE] = 3) vs 67{\%} (SE = 8) in IMP3-positive patients (log-rank test, P = 0.015). • In a multivariable analysis that adjusted for the effects of surgical margins, extracapsular extension and seminal vesicle invasion, PSA (hazard ratio [HR]: 1.04, P = 0.013), lymph node metastasis (HR: 16.7, P < 0.001) and a high pathological Gleason score (HR 4.3, P = 0.008) were significantly associated with PSA recurrence-free survival, whereas IMP3 expression was not (P = 0.11). Similarly, IMP3 expression was only associated with aggressive recurrence (HR 3.2, P = 0.006). CONCLUSION: • IMP3 expression is abnormal in approximately one-fifth of prostate cancers. Although IMP3 is differentially expressed in patients with features of biologically aggressive prostate cancer, it does not have an independent prognostic value in patients treated with RP.",
keywords = "Biomarker, IMP3, Prognosis, Prostate cancer, Recurrence",
author = "Chromecki, {Thomas F.} and Cha, {Eugene K.} and Karl Pummer and Scherr, {Douglas S.} and Tewari, {Ashutosh K.} and Maxine Sun and Harun Fajkovic and Claus Roehrborn and Raheela Ashfaq and Karakiewicz, {Pierre I.} and Shariat, {Shahrokh F.}",
year = "2012",
month = "7",
doi = "10.1111/j.1464-410X.2011.10703.x",
language = "English (US)",
volume = "110",
pages = "63--68",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Prognostic value of insulin-like growth factor II mRNA binding protein 3 in patients treated with radical prostatectomy

AU - Chromecki, Thomas F.

AU - Cha, Eugene K.

AU - Pummer, Karl

AU - Scherr, Douglas S.

AU - Tewari, Ashutosh K.

AU - Sun, Maxine

AU - Fajkovic, Harun

AU - Roehrborn, Claus

AU - Ashfaq, Raheela

AU - Karakiewicz, Pierre I.

AU - Shariat, Shahrokh F.

PY - 2012/7

Y1 - 2012/7

N2 - OBJECTIVE: • To evaluate the association of insulinlike growth factor II mRNA binding protein 3 (IMP3) with pathological features and outcomes in patients treated with radical prostatectomy (RP). PATIENTS AND METHODS: • Immunohistochemical staining for IMP3 was performed on archival tissue microarray specimens from 232 consecutive patients treated with RP for clinically localized disease. • None of the patients received neoadjuvant or adjuvant radiation or hormone therapy. • IMP3 expression was histologically categorized as normal or abnormal. • Disease recurrence was classified as aggressive if metastases were present, post-recurrence prostate-specific antigen (PSA) doubling time was less than 10 months, or if the patients failed to respond to salvage local radiation therapy. RESULTS: • The median follow-up was 69.8 months (interquartile range [IQR]: 40.1-99.5). • IMP3 expression was abnormal in 42 (18.1%) of 232 patients. • IMP3 expression was associated with extracapsular extension (P = 0.020), seminal vesicle invasion (P = 0.024), lymphovascular invasion (P = 0.036) and a high pathological Gleason score (P = 0.009). • The 5-year PSA recurrence-free survival for IMP3-negative patients was 83% (standard error [SE] = 3) vs 67% (SE = 8) in IMP3-positive patients (log-rank test, P = 0.015). • In a multivariable analysis that adjusted for the effects of surgical margins, extracapsular extension and seminal vesicle invasion, PSA (hazard ratio [HR]: 1.04, P = 0.013), lymph node metastasis (HR: 16.7, P < 0.001) and a high pathological Gleason score (HR 4.3, P = 0.008) were significantly associated with PSA recurrence-free survival, whereas IMP3 expression was not (P = 0.11). Similarly, IMP3 expression was only associated with aggressive recurrence (HR 3.2, P = 0.006). CONCLUSION: • IMP3 expression is abnormal in approximately one-fifth of prostate cancers. Although IMP3 is differentially expressed in patients with features of biologically aggressive prostate cancer, it does not have an independent prognostic value in patients treated with RP.

AB - OBJECTIVE: • To evaluate the association of insulinlike growth factor II mRNA binding protein 3 (IMP3) with pathological features and outcomes in patients treated with radical prostatectomy (RP). PATIENTS AND METHODS: • Immunohistochemical staining for IMP3 was performed on archival tissue microarray specimens from 232 consecutive patients treated with RP for clinically localized disease. • None of the patients received neoadjuvant or adjuvant radiation or hormone therapy. • IMP3 expression was histologically categorized as normal or abnormal. • Disease recurrence was classified as aggressive if metastases were present, post-recurrence prostate-specific antigen (PSA) doubling time was less than 10 months, or if the patients failed to respond to salvage local radiation therapy. RESULTS: • The median follow-up was 69.8 months (interquartile range [IQR]: 40.1-99.5). • IMP3 expression was abnormal in 42 (18.1%) of 232 patients. • IMP3 expression was associated with extracapsular extension (P = 0.020), seminal vesicle invasion (P = 0.024), lymphovascular invasion (P = 0.036) and a high pathological Gleason score (P = 0.009). • The 5-year PSA recurrence-free survival for IMP3-negative patients was 83% (standard error [SE] = 3) vs 67% (SE = 8) in IMP3-positive patients (log-rank test, P = 0.015). • In a multivariable analysis that adjusted for the effects of surgical margins, extracapsular extension and seminal vesicle invasion, PSA (hazard ratio [HR]: 1.04, P = 0.013), lymph node metastasis (HR: 16.7, P < 0.001) and a high pathological Gleason score (HR 4.3, P = 0.008) were significantly associated with PSA recurrence-free survival, whereas IMP3 expression was not (P = 0.11). Similarly, IMP3 expression was only associated with aggressive recurrence (HR 3.2, P = 0.006). CONCLUSION: • IMP3 expression is abnormal in approximately one-fifth of prostate cancers. Although IMP3 is differentially expressed in patients with features of biologically aggressive prostate cancer, it does not have an independent prognostic value in patients treated with RP.

KW - Biomarker

KW - IMP3

KW - Prognosis

KW - Prostate cancer

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=84862283677&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862283677&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2011.10703.x

DO - 10.1111/j.1464-410X.2011.10703.x

M3 - Article

C2 - 22077633

AN - SCOPUS:84862283677

VL - 110

SP - 63

EP - 68

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 1

ER -